Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Krystal Biotech Inc (KRYS)
Krystal Biotech Inc (KRYS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,997,169
  • Shares Outstanding, K 28,206
  • Annual Sales, $ 0 K
  • Annual Income, $ -139,980 K
  • 60-Month Beta 0.83
  • Price/Sales 334.37
  • Price/Cash Flow N/A
  • Price/Book 3.96
Trade KRYS with:

Options Overview Details

View History
  • Implied Volatility 59.78% ( +7.22%)
  • Historical Volatility 66.96%
  • IV Percentile 54%
  • IV Rank 25.30%
  • IV High 125.71% on 01/06/23
  • IV Low 37.45% on 08/17/23
  • Put/Call Vol Ratio 7.57
  • Today's Volume 60
  • Volume Avg (30-Day) 229
  • Put/Call OI Ratio 1.46
  • Today's Open Interest 7,200
  • Open Int (30-Day) 7,398

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.52
  • Number of Estimates 4
  • High Estimate -0.02
  • Low Estimate -0.95
  • Prior Year -1.25
  • Growth Rate Est. (year over year) +58.40%

Price Performance

See More
Period Period Low Period High Performance
1-Month
93.95 +11.68%
on 11/10/23
114.77 -8.58%
on 11/06/23
-17.23 (-14.11%)
since 11/03/23
3-Month
93.95 +11.68%
on 11/10/23
132.68 -20.92%
on 09/12/23
-21.33 (-16.90%)
since 09/01/23
52-Week
69.81 +50.29%
on 01/10/23
132.68 -20.92%
on 09/12/23
+27.42 (+35.38%)
since 12/02/22

Most Recent Stories

More News
This Stock Has Quadrupled in 5 Years. Can It Do It Again?

Have investors already missed the boat with this stock?

KRYS : 104.92 (-1.26%)
2 Soaring Stocks With More Upside Potential

Are these mid-cap stocks giants in the making?

CRSP : 71.51 (+4.17%)
KRYS : 104.92 (-1.26%)
What Will AbbVie Buy Next?

Two mid-cap drugmakers stand out as logical targets for AbbVie.

AGN.AX : 0.480 (unch)
ABBV : 144.15 (+0.52%)
BPMC : 72.72 (+0.93%)
KRYS : 104.92 (-1.26%)
Up 48% in 2023, Is This Biotech Stock a Buy?

How much longer can this biotech's run last?

KRYS : 104.92 (-1.26%)
Krystal Clear: Krystal Biotech Clears Resistance in Good Volume

Regulatory momentum, bullish Wall Street analysts and favorable technicals all suggest Krystal Biotech, Inc. may be a gem.

KRYS : 104.92 (-1.26%)
Why Shares of Krystal Biotech Are Rising Monday

The company is moving quickly to market its newly approved therapy.

KRYS : 104.92 (-1.26%)
2 Risky Stocks That Could Soar in 2023

These "exciting" companies aren't for everyone.

BLUE : 4.47 (+4.93%)
KRYS : 104.92 (-1.26%)
2 Growth Stocks That Could Double in the Next Year

Just don't be too quick to press the buy button.

KRYS : 104.92 (-1.26%)
BTAI : 3.82 (-1.80%)
Krystal Biotech Announces FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trial

KB407 is an investigational, redosable gene therapy candidate designed to treat all patients with cystic fibrosis regardless of the underlying genetic...

KRYS : 104.92 (-1.26%)
Can This Healthcare Stock Keep Beating the Market?

This biotech looks promising, but there are potential pitfalls to consider.

KRYS : 104.92 (-1.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States.

See More

Key Turning Points

3rd Resistance Point 109.68
2nd Resistance Point 108.27
1st Resistance Point 106.60
Last Price 104.92
1st Support Level 103.52
2nd Support Level 102.11
3rd Support Level 100.44

See More

52-Week High 132.68
Fibonacci 61.8% 108.66
Last Price 104.92
Fibonacci 50% 101.24
Fibonacci 38.2% 93.83
52-Week Low 69.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar